Journal of Microbiology and Biotechnology

  • 제27권11호
  • /
  • Pages.1932-1941
  • /
  • 2017
  • /
  • 1017-7825(pISSN)
  • /
  • 1738-8872(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지
DOI QR코드

DOI QR Code

In Vitro Effect of DFC-2 on Mycolic Acid Biosynthesis in Mycobacterium tuberculosis

  • Kim, Sukyung (Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University) ;
  • Seo, Hoonhee (Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University) ;
  • Mahmud, Hafij Al (Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University) ;
  • Islam, Md Imtiazul (Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University) ;
  • Kim, Yong-Sik (Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University) ;
  • Lyu, Jiwon (Department of Pulmonary and Critical Care Medicine, School of Medicine, Soonchunhyang University) ;
  • Nam, Kung-Woo (Department of Life Science and Biotechnology, Soonchunhyang University) ;
  • Lee, Byung-Eui (Department of Life Science and Biotechnology Chemistry, Soonchunhyang University) ;
  • Lee, Kee-In (Green Chemistry Division, Korea Research Institute of Chemical Technology) ;
  • Song, Ho-Yeon (Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University)
  • 투고 : 2017.05.04
  • 심사 : 2017.09.04
  • 발행 : 2017.11.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

DFC-2, a methyl 5-[2-(dimethylamino)ethoxy]-7,12-dioxo-7,12-dihydrodinaphtho[1,2-b:2',3'-d]furan-6-carboxylate, is reported to have antitubercular effects against Mycobacterium tuberculosis. At concentrations ranging from 0.19 to $0.39{\mu}g/ml$, DFC-2 inhibited both drugusceptible and -resistant strains of M. tuberculosis. Microarray analyses were employed to gain insights into the molecular mechanisms of DFC-2's action in M. tuberculosis. The most affected functional gene category was "lipid biosynthesis," which is involved in mycolic acid synthesis. The decrease in transcription of genes related to mycolic acid synthesis was confirmed by RT-PCR. Furthermore, we found that DFC-2 triggered a reduction in mycolic acid levels, showing a similar pattern to that of mycolic acid synthesis inhibitor isoniazid. These results may explain how this compound kills mycobacteria efficiently by inhibiting mycolic acid synthesis.

키워드

참고문헌

  1. World Health Organization. 2016. Global Tuberculosis Report 2016. WHO, Geneva, Switzerland.
  2. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. 2006. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3: e466. https://doi.org/10.1371/journal.pmed.0030466
  3. Jang WS, Choi YS, Kim S, Jyoti MA, Seo H, Han J , et al. 2017. Naphthofuroquinone derivatives show strong antimycobacterial activities against drug-resistant mycobacteria. J. Chemother. 29: 338-343. https://doi.org/10.1080/1120009X.2017.1296987
  4. Yajko DM, Madej JJ, Lancaster MV, Sanders CA, Cawthon VL, Gee B, et al. 1995. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J. Clin. Microbiol. 33: 2324-2327.
  5. Katawera V, Siedner M, Boum Y 2nd. 2014. Evaluation of the modified colorimetric resazurin microtiter plate-based antibacterial assay for rapid and reliable tuberculosis drug susceptibility testing. BMC Microbiol. 14: 259. https://doi.org/10.1186/s12866-014-0259-6
  6. Palomino J C, Martin A, Camacho M , Guerra H, Swings J, Portaels F. 2002. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2720-2722. https://doi.org/10.1128/AAC.46.8.2720-2722.2002
  7. Chitwood LA. 1969. Tube dilution antimicrobial susceptibility testing: efficacy of a microtechnique applicable to diagnostic laboratories. Appl. Microbiol. 17: 707-709.
  8. Turck M, Lindemeyer RI, Petersdorf RG. 1963. Comparison of single-disc and tube-dilution techniques in determining antibiotic sensitivities of gram-negative pathogens. Ann. Int. Med. 58: 56-65. https://doi.org/10.7326/0003-4819-58-1-56
  9. Hoffner S, Jimenez-Misas C, Lundin A. 1999. Improved extraction and assay of mycobacterial ATP for rapid drug susceptibility testing. Luminescence 14: 255-261. https://doi.org/10.1002/(SICI)1522-7243(199909/10)14:5<255::AID-BIO543>3.0.CO;2-W
  10. Beckers B, Lang HRM, Schimke D, Lammers A. 1985. Evaluation of a bioluminescence assay for rapid antimicrobial susceptibility testing of mycobacteria. Eur. J. Clin. Microbiol. 4: 556-561. https://doi.org/10.1007/BF02013394
  11. Nilsson LE, Hoffner SE, Ansehn S. 1988. Rapid susceptibility testing of Mycobacterium tuberculosis by bioluminescence assay of mycobacterial ATP. Antimicrob. Agents Chemother. 32: 1208-1212. https://doi.org/10.1128/AAC.32.8.1208
  12. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, et al. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19: 1157-1160. https://doi.org/10.1038/nm.3262
  13. Rao SP, Alonso S, Rand L, Dick T, Pethe K. 2008. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 105: 11945-11950. https://doi.org/10.1073/pnas.0711697105
  14. Shi L, Sohaskey CD, Pfeiffer C, Datta P, Parks M, McFadden J, et al. 2010. Carbon flux rerouting during Mycobacterium tuberculosis growth arrest. Mol. Microbiol. 78: 1199-1215. https://doi.org/10.1111/j.1365-2958.2010.07399.x
  15. Jyoti MA, Zerin T, Kim TH, Hwang TS, Jang WS, Nam KW, et al. 2015. In vitro effect of ursolic acid on the inhibition of Mycobacterium tuberculosis and its cell wall mycolic acid. Pulm. Pharmacol. Ther. 33: 17-24. https://doi.org/10.1016/j.pupt.2015.05.005
  16. Ryndak MB, Singh KK, Peng Z, Laal S. 2015. Transcriptional profile of Mycobacterium tuberculosis replicating in type II alveolar epithelial cells. PLoS One 10: e0123745. https://doi.org/10.1371/journal.pone.0123745
  17. Shi L , Jung YJ, Tyagi S , Gennaro ML, North RJ. 2003. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc. Natl. Acad. Sci. USA 100: 241-246. https://doi.org/10.1073/pnas.0136863100
  18. Jang WS, Kim S, Podder B, Jyoti MA, Nam KW, Lee BE, et al. 2015. Anti-mycobacterial activity of tamoxifen against drug-resistant and intra-macrophage Mycobacterium tuberculosis. J. Microbiol. Biotechnol. 25: 946-950. https://doi.org/10.4014/jmb.1412.12023
  19. Russo G, Zegar C, Giordano A. 2003. Advantages and limitations of microarray technology in human cancer. Oncogene 22: 6497-6507. https://doi.org/10.1038/sj.onc.1206865
  20. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544. https://doi.org/10.1038/31159
  21. Waddell S J, Stabler RA, Laing K , Kremer L, Reynolds RC, Besra GS. 2004. The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds. Tuberculosis (Edinb.) 84: 263-274. https://doi.org/10.1016/j.tube.2003.12.005
  22. Tavazoie S, Hughes JD, Campbell MJ, Cho R J, Church GM. 1999. Systematic determination of genetic network architecture. Nat. Genet. 22: 281-285. https://doi.org/10.1038/10343
  23. Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, Belcher CE, et al. 2002. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc. Natl. Acad. Sci. USA 99: 972-977. https://doi.org/10.1073/pnas.231625398
  24. Pawelczyk J, Kremer L. 2014. The molecular genetics of mycolic acid biosynthesis. Microbiol. Spectr. 2: MGM2-0003-2013.
  25. Parrish NM, Ko CG, Hughes MA, Townsend CA, Dick JD. 2004. Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG. J. Antimicrob. Chemother. 54: 722-729. https://doi.org/10.1093/jac/dkh408
  26. Takayama K, Wang L, David HL. 1972. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2: 29-35. https://doi.org/10.1128/AAC.2.1.29
  27. Parumasivam T, Kumar HSN, Mohamad S, Ibrahim P, Sadikun A. 2013. Effects of a lipophilic isoniazid derivative on the growth and cellular morphogenesis of Mycobacterium tuberculosis H37Rv. Int. J. Pharm. Pharm. Sci. 5: 43-50.
  28. Barkan D, Liu Z , Sacchettini J C, Glickman MS. 2009. Mycolic acid cyclopropanation is essential for viability, drug resistance, and cell wall integrity of Mycobacterium tuberculosis. Chem. Biol. 16: 499-509. https://doi.org/10.1016/j.chembiol.2009.04.001
  29. Bhatt A , Molle V , Besra G S, Jacobs WR Jr, Kremer L. 2007. The Mycobacterium tuberculosis FAS-II condensing enzymes:their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development. Mol. Microbiol. 64: 1442-1454. https://doi.org/10.1111/j.1365-2958.2007.05761.x
  30. Salzman V, Mondino S, Sala C, Cole ST, Gago G, Gramajo H. 2010. Transcriptional regulation of lipid homeostasis in mycobacteria. Mol. Microbiol. 78: 64-77.
  31. Fisher MA, Plikaytis BB, Shinnick TM. 2002. Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J. Bacteriol. 184: 4025-4032. https://doi.org/10.1128/JB.184.14.4025-4032.2002
  32. Betts JC, McLaren A, Lennon MG, Kelly FM, Lukey PT, Blakemore SJ, et al. 2003. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosantreated Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47: 2903-2913. https://doi.org/10.1128/AAC.47.9.2903-2913.2003
  33. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230. https://doi.org/10.1126/science.8284673

피인용 문헌

  1. Latest Comprehensive Knowledge of the Crosstalk between TLR Signaling and Mycobacteria and the Antigens Driving the Process vol.29, pp.10, 2019, https://doi.org/10.4014/jmb.1908.08057